Swiss Rockets AG Acquires Complete Genomics
Swiss Rockets AG, based in Basel, Switzerland, announced on February 23 that it entered into a definitive agreement to acquire Complete Genomics, Inc. Complete Genomics is a leader in whole human genomic sequencing, which is used by research centers to conduct medical research that, in the future, is expected to be used to improve both prevention and treatment of disease. Since its founding in 2005, the company has been at the forefront of high-throughput, cost-effective sequencing innovation, supporting more than 10,900 scientific publications worldwide. Swiss Rockets is a portfolio of biotechnology companies. Its portfolio includes radioligand therapies, small molecules... Read More »
Gilead Inks $7.8 Billion Deal to Purchase Arcellx
On February 23, Gilead Sciences, Inc. announced that it has entered into a definitive agreement to acquire Arcellx, Inc. Under the terms of the agreement, Arcellx shareholders will receive $115 per share in cash at closing plus one contingent value right of $5 per share, representing an implied equity value of $7.8 billion payable at closing. Arcellx is a clinical-stage biotechnology company focused on delivering a new class of immunotherapies for patients with cancer and other incurable diseases. Arcellx’s lead pipeline candidate, anitocabtagene autoleucel (anito-cel), is currently in a Phase 2 pivotal trial for patients with relapsed or refractory multiple myeloma. According to its most... Read More »
GSK’s Tesaro Acquires Alteogen’s ALT-B4
GSK announced on January 20 that its portfolio company, Tesaro, will acquire Alteogen’s novel hyaluronidase enzyme ALT-B4 for $20 million. Alteogen developed ALT-B4 using its bespoke Hybrozyme technology, which the company notes was designed to boost the flexibility and stability of protein structures while preserving the enzyme’s original mechanism of action. Tesaro is a biopharmaceutical company whose major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor, is currently approved for use in ovarian cancer. It is owned by GSK. The original press release notes that Tesaro plans to use the tech to develop and potentially market... Read More »
GSK Acquires Rapt Therapeutics For $2.2 Billion
In its first transaction of the year, GSK Plc, announced that it acquired Rapt Therapeutics, Inc. for $58 per share. That price equates to an aggregate equity value of $2.2 billion, according to GSK, which added that the upfront investment net of cash acquired comes to $1.9 billion. Net of cash acquired, GSK’s estimated upfront investment is $1.9 billion. Based in South San Francisco, California, RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients. It develops novel therapies that are designed to modulate the critical immune responses underlying these diseases. According to a... Read More »
Sanofi Acquires Dynavax Technologies for $2.2 Billion
Sanofi is rounding out 2025 with a multi-billion-dollar transaction. On December 24, the company announced that it entered into an agreement to acquire Dynavax Technologies Corporation, based in Emeryville, California. Under the terms of the agreement, Sanofi will commence a cash tender offer to acquire all outstanding shares of Dynavax for $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion. Dynavax Technologies is a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate (Z-1018). According to its most recent annual SEC filing, Dynavax reported approximately $277.2 million... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
